Traynor Capital Management, Inc.
Source: SEC Form 13F · as of Mar 2026Traynor Capital Management, Inc. holds 19 biotech & pharma companies tracked by BioSniper, totaling $107.8M in value as of Mar 2026 (SEC Form 13F).
Companies held
19
Total value held
$107.8M
| Company | Shares | Value |
|---|---|---|
| LLYELI LILLY & Co | 54,594 | $48.4M |
| REGNREGENERON PHARMACEUTICALS, INC. | 31,466 | $23.6M |
| NVONovo Nordisk A/S | 418,675 | $14.8M |
| VRTXVERTEX PHARMACEUTICALS INC / MA | 11,806 | $5.2M |
| ABBVAbbVie Inc. | 20,941 | $4.5M |
| ALNYALNYLAM PHARMACEUTICALS, INC. | 12,592 | $4.0M |
| MRKMerck & Co., Inc. | 22,515 | $2.7M |
| PMPhilip Morris International Inc | 4,513 | $744K |
| JNJJOHNSON & JOHNSON | 3,052 | $740K |
| NVSNovartis AG | 3,782 | $569K |
| PFEPFIZER INC | 17,761 | $493K |
| UNHUnitedHealth Group Incorporated Common Stock (DE) | 1,879 | $492K |
| BMYBRISTOL MYERS SQUIBB CO | 7,540 | $450K |
| CAHCardinal Health Inc. | 2,152 | $444K |
| AMGNAMGEN INC | 920 | $321K |
| ABTABBOTT LABORATORIES | 2,695 | $275K |
| NGENNERVGEN PHARMA CORP. | 25,500 | $95K |
| ESPREsperion Therapeutics, Inc. | 14,386 | $38K |
| AKBAAkebia Therapeutics, Inc. | 14,600 | $19K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.